Literature DB >> 3887173

Immune responses elicited by vaccinations with Candida albicans ribosomes in cyclophosphamide treated animals.

E Segal, H Sandovsky-Losica, S Nussbaum.   

Abstract

This study describes humoral and cell mediated immune (CMI) responses detected in cyclophosphamide (CY) treated animals who were vaccinated with Candida albicans ribosomes and were protected against systemic candidiasis (previous study). Mice treated with CY and vaccinated with C. albicans ribosomes revealed CMI responses towards the ribosomes as measured in vivo by the foot pad swelling test and in vitro by the lymphocyte transformation assay. Both reactions were higher in CY treated and ribosome vaccinated mice than in controls (mice that were only vaccinated). Humoral immune responses were measured by the enzyme linked immunosorbent assay (ELISA). Anti ribosomal antibody titer contrary to the CMI responses was lower in CY treated animals than in non treated controls. These data point to a possible explanation of the mechanisms underlying the ribosomal vaccinations in CY treated hosts, and show the potential of such vaccinations in compromised individuals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3887173     DOI: 10.1007/bf00431479

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  14 in total

1.  Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1978-07       Impact factor: 3.441

2.  Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes.

Authors:  W O Schalla; W Johnson
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

3.  Immunization of mice with Trypanosoma cruzi polyribosomes.

Authors:  L L Leon; W Leon; L Chaves; S C Costa; M Q Cruz; H M Brascher; A O Lima
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

4.  Cell-mediated immunity following experimental vaccinations with Candida albicans ribosomes.

Authors:  R Levy; E Segal; E Eylan; L Barr-Nea
Journal:  Mycopathologia       Date:  1983-11-25       Impact factor: 2.574

5.  Experimental mycosis in immunosuppressed rabbits. I. Acute and chronic candidosis.

Authors:  J W Rippon; D N Anderson
Journal:  Mycopathologia       Date:  1978-10-16       Impact factor: 2.574

6.  Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions.

Authors:  R Levy; E Segal; E Eylan
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

7.  Cyclophosphamide effects on murine cryptococcosis.

Authors:  J R Graybill; L Mitchell
Journal:  Infect Immun       Date:  1978-08       Impact factor: 3.441

8.  Experimental vaccination with Candida albicans ribosomes in cyclophosphamide-treated animals.

Authors:  E Segal; H Sandovsky-Losica
Journal:  Sabouraudia       Date:  1981-12

9.  Effects of cyclophosphamide on murine candidiasis.

Authors:  S A Moser; J E Domer
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

10.  Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

View more
  2 in total

1.  Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.

Authors:  S Mizutani; M Endo; T Ino-Ue; M Kurasawa; Y Uno; H Saito; I Kato; K Takesako
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  CD4(+)-T-Cell-mediated resistance to systemic murine candidiasis induced by a membrane fraction of Candida albicans.

Authors:  S Mizutani; M Endo; T Ino-Ue; M Kurasawa; Y Uno; H Saito; K Onogi; I Kato; K Takesako
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.